Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00848601
Recruitment Status : Terminated (The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in patients with refractory prostate and lymphoma)
First Posted : February 20, 2009
Last Update Posted : December 2, 2011
Information provided by (Responsible Party):
Astex Pharmaceuticals

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : October 2010
  Actual Study Completion Date : October 2010